Copyright
©The Author(s) 2021.
World J Gastroenterol. Nov 14, 2021; 27(42): 7387-7401
Published online Nov 14, 2021. doi: 10.3748/wjg.v27.i42.7387
Published online Nov 14, 2021. doi: 10.3748/wjg.v27.i42.7387
Subgroups | OS (mo) | PFS (mo) | 5-yr survival (%) | |
Median/n, range/% | Median/n, range/% | |||
Treatment | F-IGRT (n = 27) | 21.0, 0-87 | 12.0, 0-74 | 47.2 |
S-IGRT (n = 4) | 17.0, 3-49 | 18.0, 2-32 | 0.0 | |
Intent | Curative (n = 23) | 22.0, 0-87 | 14.0, 0-74 | 51.5 |
Palliative (n = 8) | 8.0, 0-79 | 4, 0-13 | 30.0 | |
Location | Oesophageal (n = 22) | 18, 0-87 | 13, 0-74 | 42.8 |
SCC (n = 16) | 20, 1-87 | 14, 1-74 | 62.0 | |
AC (n = 6) | 10, 0-54 | 7, 0-19 | 0.0 | |
Gastric (n=9) | 25, 0-79 | 13, 0-53 | 55.6 |
- Citation: Be KH, Khor R, Lim Joon D, Starvaggi B, Chao M, Ng SP, Ng M, Zorron Cheng Tao Pu L, Efthymiou M, Vaughan R, Chandran S. Long-term clinical outcomes of lipiodol marking using standard gastroscopy for image-guided radiotherapy of upper gastrointestinal cancers. World J Gastroenterol 2021; 27(42): 7387-7401
- URL: https://www.wjgnet.com/1007-9327/full/v27/i42/7387.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i42.7387